Influenza
Conditions
Keywords
Influenza vaccine GSK576389A, Influenza infection, Fluarix
Brief summary
In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals' influenza vaccine administered in adults aged 65 years and older compared to Fluarix.
Detailed description
There are 10 parallel groups: 9 observer blinded groups with subjects 65 years and older receiving an investigational vaccine or Fluarix, and 1 open group with subjects between 18 and 40 years old receiving Fluarix. CMI response will be determined for a subset only. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
BIOLOGICALGlaxoSmithKline Biologicals' influenza vaccine GSK576389A
Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
BIOLOGICALFluarix
Single dose, Intramuscular injection
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female aged 18-40 years old or 65 years or older at the time of the vaccination. * Written informed consent obtained from the subject. * Free of an acute aggravation of the health status as established by clinical evaluation (medical history and medical history directed examination) before entering into the study. * If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.
Exclusion criteria
* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period. * Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. * Planned administration of a vaccine not foreseen by the study protocol during the entire study period. * Planned administration of an influenza vaccine other than the study vaccines during the entire study period. * Vaccination against influenza since January 2007 (with 2007/2008 or 2006/2007 influenza vaccine). * Administration of more than 14 days of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination * Hypersensitivity to a previous dose of influenza vaccine. * Allergy to any component of the vaccine. * Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality. * Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature\<37.5ºC (99.5ºF). * Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study. * Any medical conditions in which IM injections are contraindicated. * Lactating female or female planning to become pregnant or to discontinue contraceptive precautions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Haemagglutination Inhibition (HI) Antibody Titers | At Day 21 | Antibody titers were expressed as Geometric mean titers (GMTs) against each of the 3 vaccine strains in greater than or equal to 65 years age groups only. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HI Antibody Titers at Day 180 | At Day 180 | Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The Number of Subjects Seroconverted to HI Antibodies at Day 21 | At Day 21 | A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The Number of Subjects Seroconverted to HI Antibodies at Day 180 | At Day 180 | A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| HI Antibody Seroconversion Factors at Day 21 | At Day 21 | Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| HI Antibody Seroconversion Factors at Day 180 | At Day 180 | Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | At Day 0 and 21 | A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The Number of Subjects Seroprotected to HI Antibodies at Day 180 | At Day 180 | A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | At Days 0 and 21 | The markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD4-CD40Ligand(L), CD4-interferon gamma (CD4-IFNγ), CD4-interleukin 2 (CD4-IL2) and CD4-tumor necrosis factor alpha (CD4-TNFα). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | At Day 180 | The markers assessed were CD4-All doubles, CD4-CD40L, CD4-IFNγ, CD4-IL2 and CD4-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | At Days 0 and 21 | The markers assessed were Cluster of Differentiation 8-All doubles i.e. CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| HI Antibody Titers at Day 0 and Day 21 | At Day 0 and 21 | Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | During a 7-day follow-up period (Day 0-6) after vaccination | Grade 3 ecchymosis, pain, redness and swelling was greater than 100 millimeter (mm) i.e. \> 100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was \>20mm. |
| Duration of Solicited Local AEs | During a 7-day follow-up period (Day 0-6) after vaccination | Duration was defined as number of days with any grade of local symptoms. |
| Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | During a 7-day follow-up period (Day 0-6) after vaccination | Any Fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e.≥ 38.0°C, grade 3 fever was axillary temperature \>40°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination. |
| Duration of Solicited General AEs | During a 7-day follow-up period (Day 0-6) after vaccination | Duration was defined as number of days with any grade of general symptoms. |
| Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | During a 21-day follow-up period (Day 0-20) after vaccination | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination. |
| Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Between Day 0 and Day 20 after vaccination | For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination. |
| Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Between Day 21 and Day 179 after vaccination | For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination. |
| Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Between Day 0 and Day 20 after vaccination | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination. |
| Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Between Day 21 and Day 179 after vaccination | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination. |
| The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | At Day 180 | The markers assessed were CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
Countries
Germany, Netherlands, Sweden, United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A. | 204 |
| Influenza Vaccine GSK576389A Formulation 2 Group Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A. | 202 |
| Influenza Vaccine GSK576389A Formulation 3 Group Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A. | 202 |
| Influenza Vaccine GSK576389A Formulation 4 Group Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A. | 202 |
| Influenza Vaccine GSK576389A Formulation 5 Group Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A. | 199 |
| Influenza Vaccine GSK576389A Formulation 6 Group Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A. | 198 |
| Influenza Vaccine GSK576389A Formulation 7 Group Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A. | 198 |
| Influenza Vaccine GSK576389A Formulation 8 Group Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A. | 199 |
| Fluarix Elderly Group Subjects aged ≥65 years received one dose of Fluarix vaccine. | 200 |
| Fluarix Young Group Subjects aged 18-40 years received one dose of Fluarix vaccine. | 203 |
| Total | 2,007 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 |
| Overall Study | Lost to Follow-up | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Influenza Vaccine GSK576389A Formulation 1 Group | Influenza Vaccine GSK576389A Formulation 2 Group | Influenza Vaccine GSK576389A Formulation 3 Group | Influenza Vaccine GSK576389A Formulation 4 Group | Influenza Vaccine GSK576389A Formulation 5 Group | Influenza Vaccine GSK576389A Formulation 6 Group | Influenza Vaccine GSK576389A Formulation 7 Group | Influenza Vaccine GSK576389A Formulation 8 Group | Fluarix Elderly Group | Fluarix Young Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 72.7 Years STANDARD_DEVIATION 5.75 | 72.6 Years STANDARD_DEVIATION 5.16 | 72.4 Years STANDARD_DEVIATION 5.62 | 72.9 Years STANDARD_DEVIATION 6.09 | 72.6 Years STANDARD_DEVIATION 5.66 | 72.7 Years STANDARD_DEVIATION 5.56 | 72.6 Years STANDARD_DEVIATION 5.67 | 73.0 Years STANDARD_DEVIATION 6.03 | 72.7 Years STANDARD_DEVIATION 5.43 | 27.4 Years STANDARD_DEVIATION 6.25 | 68.11 Years STANDARD_DEVIATION 14.81 |
| Sex: Female, Male Female | 95 Participants | 109 Participants | 105 Participants | 100 Participants | 89 Participants | 102 Participants | 96 Participants | 95 Participants | 90 Participants | 103 Participants | 984 Participants |
| Sex: Female, Male Male | 109 Participants | 93 Participants | 97 Participants | 102 Participants | 110 Participants | 96 Participants | 102 Participants | 104 Participants | 110 Participants | 100 Participants | 1023 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 107 / 204 | 129 / 202 | 150 / 202 | 121 / 202 | 138 / 199 | 158 / 198 | 134 / 198 | 155 / 199 | 74 / 200 | 133 / 203 |
| serious Total, serious adverse events | 18 / 204 | 9 / 202 | 5 / 202 | 8 / 202 | 9 / 199 | 10 / 198 | 16 / 198 | 19 / 199 | 15 / 200 | 3 / 203 |
Outcome results
Primary
Haemagglutination Inhibition (HI) Antibody Titers
Antibody titers were expressed as Geometric mean titers (GMTs) against each of the 3 vaccine strains in greater than or equal to 65 years age groups only. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain | 276.2 titer |
| Influenza Vaccine GSK576389A Formulation 1 Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain | 147.1 titer |
| Influenza Vaccine GSK576389A Formulation 1 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain | 82.3 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain | 102.2 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain | 163.1 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain | 350.2 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain | 98.2 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain | 172.1 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain | 351.3 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain | 91.7 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain | 152.4 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain | 309.2 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain | 181.4 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain | 331.1 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain | 113.2 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain | 202.0 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain | 114.4 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain | 438.1 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain | 78.5 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain | 263.3 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain | 155.7 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain | 174.6 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain | 111.8 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain | 347.5 titer |
| Fluarix Elderly Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain | 153.0 titer |
| Fluarix Elderly Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain | 186.7 titer |
| Fluarix Elderly Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain | 59.6 titer |
Secondary
Duration of Solicited General AEs
Duration was defined as number of days with any grade of general symptoms.
Time frame: During a 7-day follow-up period (Day 0-6) after vaccination
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom and completed information on duration in their symptom sheet.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 3.0 Days |
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.5 Days |
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 1.5 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | 3.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | 1.5 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | 1.5 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.5 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 1.5 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.5 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | NA Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 2.5 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 1.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 3.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Myalgia (N=20;35;57;30;47;66;46;56;19;40) | 2.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Shivering (N=13;18;37;26;18;43;17;31;8;21) | 1.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Nausea (N=10;12;19;10;13;18;8;14;6;13) | 1.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Fatigue (N=34;35;54;35;46;55;38;63;24;41) | 2.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Arthralgia (N=15;23;36;16;21;45;28;35;16;12) | 2.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Headache (N=22;38;47;35;39;55;36;48;23;45) | 2.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Fever (N=4;3;9;4;3;14;6;12;0;1) | 1.0 Days |
Secondary
Duration of Solicited Local AEs
Duration was defined as number of days with any grade of local symptoms.
Time frame: During a 7-day follow-up period (Day 0-6) after vaccination
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom and completed information on duration in their symptom sheet.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | 5.0 Days |
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 1.5 Days |
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 1 Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | 6.0 Days |
| Influenza Vaccine GSK576389A Formulation 2 Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 3.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 2.5 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | 6.0 Days |
| Influenza Vaccine GSK576389A Formulation 3 Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 1.0 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 3.0 Days |
| Influenza Vaccine GSK576389A Formulation 4 Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 5 Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | 2.5 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 3.0 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | 3.0 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 6 Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 3.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 7 Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | 3.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | 3.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Influenza Vaccine GSK576389A Formulation 8 Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 3.0 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | 5.0 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 1.0 Days |
| Fluarix Young Group | Duration of Solicited Local AEs | Pain (N=68;82;111;84;91;119;93;106;32;93) | 2.0 Days |
| Fluarix Young Group | Duration of Solicited Local AEs | Ecchymosis (N=3;1;5;1;2;2;4;2;3;0) | NA Days |
| Fluarix Young Group | Duration of Solicited Local AEs | Swelling (N=12;12;24;12;17;23;11;25;5;2) | 1.5 Days |
| Fluarix Young Group | Duration of Solicited Local AEs | Redness (N=14;16;35;11;33;36;18;34;5;2) | 1.0 Days |
Secondary
HI Antibody Seroconversion Factors at Day 180
Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 180
Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 2.9 fold increase |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 2.2 fold increase |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 1.7 fold increase |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 1.7 fold increase |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 2.7 fold increase |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 3.3 fold increase |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 3.5 fold increase |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 2.9 fold increase |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 1.7 fold increase |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 2.0 fold increase |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 3.0 fold increase |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 1.4 fold increase |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 2.4 fold increase |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 3.3 fold increase |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 1.4 fold increase |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 3.1 fold increase |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 1.8 fold increase |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 3.5 fold increase |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 1.5 fold increase |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 2.1 fold increase |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 2.9 fold increase |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 3.8 fold increase |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 1.6 fold increase |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 2.5 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 1.5 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 2.2 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 1.6 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors at Day 180 | A/Solomon Islands strain | 5.7 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors at Day 180 | A/Wisconsin strain | 4.0 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors at Day 180 | B/Malaysia strain | 5.6 fold increase |
Secondary
HI Antibody Seroconversion Factors at Day 21
Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 2.5 fold increase |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 4.6 fold increase |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 7.7 fold increase |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 6.8 fold increase |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 9.4 fold increase |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 3.0 fold increase |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 9.8 fold increase |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 7.9 fold increase |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 3.0 fold increase |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 4.7 fold increase |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 2.4 fold increase |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 8.6 fold increase |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 9.4 fold increase |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 2.3 fold increase |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 5.4 fold increase |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 11.6 fold increase |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 3.2 fold increase |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 7.8 fold increase |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 4.8 fold increase |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 2.7 fold increase |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 7.7 fold increase |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 2.8 fold increase |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 10.8 fold increase |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 6.0 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 5.6 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 3.1 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 2.3 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors at Day 21 | A/Solomon Islands strain | 12.8 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors at Day 21 | B/Malaysia strain | 12.0 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors at Day 21 | A/Wisconsin strain | 7.9 fold increase |
Secondary
HI Antibody Titers at Day 0 and Day 21
Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 0 and 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 276.2 titer |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 82.3 titer |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 59.9 titer |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 58.6 titer |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 147.1 titer |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 10.6 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 10.8 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 102.2 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 350.2 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 163.1 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 51.2 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 53.7 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 44.4 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 172.1 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 351.3 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 10.1 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 98.2 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 57.0 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 91.7 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 62.6 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 65.7 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 309.2 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 152.4 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 10.6 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 12.0 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 61.1 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 113.2 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 77.8 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 331.1 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 181.4 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 62.9 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 55.8 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 9.9 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 114.4 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 438.1 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 202.0 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 155.7 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 263.3 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 54.6 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 10.2 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 58.2 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 78.5 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 62.6 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 10.3 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 57.8 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 174.6 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 111.8 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 347.5 titer |
| Fluarix Elderly Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 153.0 titer |
| Fluarix Elderly Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 186.7 titer |
| Fluarix Elderly Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 61.0 titer |
| Fluarix Elderly Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 59.6 titer |
| Fluarix Elderly Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 66.5 titer |
| Fluarix Elderly Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 10.7 titer |
| Fluarix Young Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 0 | 21.3 titer |
| Fluarix Young Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 21 | 281.9 titer |
| Fluarix Young Group | HI Antibody Titers at Day 0 and Day 21 | B/Malaysia strain at Day 0 | 23.4 titer |
| Fluarix Young Group | HI Antibody Titers at Day 0 and Day 21 | A/Solomon Islands strain at Day 21 | 271.6 titer |
| Fluarix Young Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 0 | 47.8 titer |
| Fluarix Young Group | HI Antibody Titers at Day 0 and Day 21 | A/Wisconsin strain at Day 21 | 380.2 titer |
Secondary
HI Antibody Titers at Day 180
Antibody titers were expressed as GMTs in all the vaccine groups. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 180
Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 92.7 titer |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 131.5 titer |
| Influenza Vaccine GSK576389A Formulation 1 Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 30.6 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 94.3 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 35.1 titer |
| Influenza Vaccine GSK576389A Formulation 2 Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 139.8 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 133.4 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 36.3 titer |
| Influenza Vaccine GSK576389A Formulation 3 Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 100.9 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 134.0 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 87.4 titer |
| Influenza Vaccine GSK576389A Formulation 4 Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 32.5 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 109.2 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 144.7 titer |
| Influenza Vaccine GSK576389A Formulation 5 Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 40.4 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 111.4 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 33.7 titer |
| Influenza Vaccine GSK576389A Formulation 6 Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 181.4 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 89.0 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 29.9 titer |
| Influenza Vaccine GSK576389A Formulation 7 Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 118.2 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 145.3 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 39.8 titer |
| Influenza Vaccine GSK576389A Formulation 8 Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 97.7 titer |
| Fluarix Elderly Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 92.5 titer |
| Fluarix Elderly Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 23.7 titer |
| Fluarix Elderly Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 96.6 titer |
| Fluarix Young Group | HI Antibody Titers at Day 180 | B/Malaysia strain | 132.4 titer |
| Fluarix Young Group | HI Antibody Titers at Day 180 | A/Solomon Islands strain | 114.7 titer |
| Fluarix Young Group | HI Antibody Titers at Day 180 | A/Wisconsin strain | 193.2 titer |
Secondary
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Grade 3 ecchymosis, pain, redness and swelling was greater than 100 millimeter (mm) i.e. \> 100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. Any for ecchymosis, redness and swelling was \>20mm.
Time frame: During a 7-day follow-up period (Day 0-6) after vaccination
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 68 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 15 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 12 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 16 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 82 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 111 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 5 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 25 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 37 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 84 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 12 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 33 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 18 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 91 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 23 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 36 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 119 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 18 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 11 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 93 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 106 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 34 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 25 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 5 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 32 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 3 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 5 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 2 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 2 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 93 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 0 Subjects |
Secondary
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
Time frame: Between Day 0 and Day 20 after vaccination
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 1 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Related SAE(s) | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 and Day 20 | Any SAE(s) | 0 Subjects |
Secondary
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
Time frame: Between Day 21 and Day 179 after vaccination
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 18 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 9 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 5 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 8 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 9 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 10 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 16 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 19 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 15 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 1 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Related SAE(s) | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 and Day 179 | Any SAE(s) | 3 Subjects |
Secondary
Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20
For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.
Time frame: Between Day 0 and Day 20 after vaccination
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 15 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 10 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 19 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 15 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 16 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 14 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 11 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 4 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 10 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 1 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 1 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Grade 3 AE(s) | 1 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Any AE(S) | 13 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 0 and Day 20 | Related AE(s) | 2 Subjects |
Secondary
Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179
For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a symptom that prevented normal activity. Related was a symptom assessed by the investigator as causally related to the study vaccination.
Time frame: Between Day 21 and Day 179 after vaccination
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 78 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 18 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 11 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 60 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 79 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 71 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 65 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 10 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 12 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 67 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 67 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 17 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 15 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 69 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 17 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 69 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 1 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Any AE (s) | 62 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Related AE(s) | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Adverse Events Resulting in Medically Attended Visit Between Day 21 and Day 179 | Grade 3 AE(s) | 10 Subjects |
Secondary
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any Fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e.≥ 38.0°C, grade 3 fever was axillary temperature \>40°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.
Time frame: During a 7-day follow-up period (Day 0-6) after vaccination
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 11 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 15 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 22 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 21 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 9 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 6 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 20 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 14 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 34 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 10 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 38 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 35 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 23 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 14 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 35 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 18 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 24 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 29 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 15 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 9 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 23 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 12 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 19 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 28 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 47 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 37 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 57 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 46 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 10 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 39 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 26 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 36 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 30 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 54 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 30 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 35 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 24 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 5 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 10 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 21 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 16 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 26 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 18 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 35 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 10 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 20 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 24 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 8 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 7 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 46 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 39 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 18 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 16 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 21 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 47 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 36 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 35 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 27 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 6 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 9 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 28 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 66 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 46 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 38 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 18 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 43 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 5 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 45 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 27 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 55 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 55 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 15 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 34 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 8 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 38 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 36 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 25 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 12 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 46 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 28 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 20 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 17 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 63 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 35 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 35 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 48 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 14 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 27 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 25 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 4 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 44 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 31 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 2 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 10 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 6 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 21 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 56 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 2 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 6 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 16 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 19 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 4 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 24 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 23 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 20 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 16 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 8 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 9 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 15 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 0 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 6 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 40 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 21 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 30 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 9 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 30 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 12 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 33 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 1 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 11 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 1 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 1 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 16 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 41 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 45 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 1 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 2 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 13 Subjects |
Secondary
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.
Time frame: During a 21-day follow-up period (Day 0-20) after vaccination
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 41 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 5 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 7 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 32 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 15 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 51 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 8 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 6 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 39 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 3 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 34 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 0 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 6 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 13 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 42 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 34 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 8 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 1 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 18 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 6 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 43 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 27 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 1 Subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 6 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 44 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 13 Subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 3 Subjects |
Secondary
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
The markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD4-CD40Ligand(L), CD4-interferon gamma (CD4-IFNγ), CD4-interleukin 2 (CD4-IL2) and CD4-tumor necrosis factor alpha (CD4-TNFα). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Days 0 and 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 234.99 cells per million CD4 T-cells | Standard Deviation 298.31 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 202.65 cells per million CD4 T-cells | Standard Deviation 195.65 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 203.89 cells per million CD4 T-cells | Standard Deviation 281.14 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 181.54 cells per million CD4 T-cells | Standard Deviation 242.6 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 407.18 cells per million CD4 T-cells | Standard Deviation 456.82 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 716.86 cells per million CD4 T-cells | Standard Deviation 601.16 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 644.07 cells per million CD4 T-cells | Standard Deviation 707.63 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 187.19 cells per million CD4 T-cells | Standard Deviation 277.14 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 583.77 cells per million CD4 T-cells | Standard Deviation 563.98 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 941.04 cells per million CD4 T-cells | Standard Deviation 994.45 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 791.31 cells per million CD4 T-cells | Standard Deviation 616.06 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 1016.63 cells per million CD4 T-cells | Standard Deviation 990.97 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 351.26 cells per million CD4 T-cells | Standard Deviation 450.82 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 509.26 cells per million CD4 T-cells | Standard Deviation 451.2 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 555.20 cells per million CD4 T-cells | Standard Deviation 555.43 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 91.32 cells per million CD4 T-cells | Standard Deviation 201.6 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 177.48 cells per million CD4 T-cells | Standard Deviation 278.18 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 926.13 cells per million CD4 T-cells | Standard Deviation 749.19 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 398.57 cells per million CD4 T-cells | Standard Deviation 370.41 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 361.99 cells per million CD4 T-cells | Standard Deviation 378.72 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 1025.01 cells per million CD4 T-cells | Standard Deviation 736.55 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 299.14 cells per million CD4 T-cells | Standard Deviation 421.84 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 418.24 cells per million CD4 T-cells | Standard Deviation 523.39 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 406.48 cells per million CD4 T-cells | Standard Deviation 508.99 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 277.98 cells per million CD4 T-cells | Standard Deviation 394.46 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 712.96 cells per million CD4 T-cells | Standard Deviation 700.26 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 441.16 cells per million CD4 T-cells | Standard Deviation 517.73 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 387.03 cells per million CD4 T-cells | Standard Deviation 429.86 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 336.70 cells per million CD4 T-cells | Standard Deviation 352.2 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 747.93 cells per million CD4 T-cells | Standard Deviation 778.49 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 458.02 cells per million CD4 T-cells | Standard Deviation 373.43 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 1614.14 cells per million CD4 T-cells | Standard Deviation 953.74 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 440.26 cells per million CD4 T-cells | Standard Deviation 451.77 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 596.53 cells per million CD4 T-cells | Standard Deviation 400.24 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 488.70 cells per million CD4 T-cells | Standard Deviation 540.66 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 403.08 cells per million CD4 T-cells | Standard Deviation 319.99 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 1491.86 cells per million CD4 T-cells | Standard Deviation 899.5 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 193.42 cells per million CD4 T-cells | Standard Deviation 297.22 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 190.19 cells per million CD4 T-cells | Standard Deviation 245.89 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 1163.80 cells per million CD4 T-cells | Standard Deviation 865.47 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 806.86 cells per million CD4 T-cells | Standard Deviation 561.77 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 350.04 cells per million CD4 T-cells | Standard Deviation 325.28 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 1570.30 cells per million CD4 T-cells | Standard Deviation 962.36 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 382.61 cells per million CD4 T-cells | Standard Deviation 428.51 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 1082.78 cells per million CD4 T-cells | Standard Deviation 712.53 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 239.73 cells per million CD4 T-cells | Standard Deviation 260.28 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 1295.22 cells per million CD4 T-cells | Standard Deviation 856.91 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 664.46 cells per million CD4 T-cells | Standard Deviation 582.79 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 491.65 cells per million CD4 T-cells | Standard Deviation 369.85 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 891.98 cells per million CD4 T-cells | Standard Deviation 719.87 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 1438.93 cells per million CD4 T-cells | Standard Deviation 881.8 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 636.42 cells per million CD4 T-cells | Standard Deviation 570.57 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 477.12 cells per million CD4 T-cells | Standard Deviation 531.36 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 283.18 cells per million CD4 T-cells | Standard Deviation 319.74 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 155.22 cells per million CD4 T-cells | Standard Deviation 184.44 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 587.72 cells per million CD4 T-cells | Standard Deviation 396.47 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 657.41 cells per million CD4 T-cells | Standard Deviation 684.48 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 944.29 cells per million CD4 T-cells | Standard Deviation 589.91 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 856.00 cells per million CD4 T-cells | Standard Deviation 685.35 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 285.19 cells per million CD4 T-cells | Standard Deviation 319.8 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 158.04 cells per million CD4 T-cells | Standard Deviation 192.23 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 188.29 cells per million CD4 T-cells | Standard Deviation 215.39 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 322.07 cells per million CD4 T-cells | Standard Deviation 631.98 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 855.95 cells per million CD4 T-cells | Standard Deviation 1073.89 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 601.64 cells per million CD4 T-cells | Standard Deviation 763.9 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 559.98 cells per million CD4 T-cells | Standard Deviation 642.32 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 225.66 cells per million CD4 T-cells | Standard Deviation 501.91 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 516.80 cells per million CD4 T-cells | Standard Deviation 421.85 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 992.50 cells per million CD4 T-cells | Standard Deviation 1134.21 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 204.49 cells per million CD4 T-cells | Standard Deviation 236.05 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 852.44 cells per million CD4 T-cells | Standard Deviation 637.3 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 704.14 cells per million CD4 T-cells | Standard Deviation 778.07 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 584.25 cells per million CD4 T-cells | Standard Deviation 626.26 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 432.24 cells per million CD4 T-cells | Standard Deviation 487.63 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 1140.56 cells per million CD4 T-cells | Standard Deviation 955.61 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 333.95 cells per million CD4 T-cells | Standard Deviation 487.76 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 500.81 cells per million CD4 T-cells | Standard Deviation 734.64 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 1005.72 cells per million CD4 T-cells | Standard Deviation 1314.69 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 193.56 cells per million CD4 T-cells | Standard Deviation 236.01 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 130.19 cells per million CD4 T-cells | Standard Deviation 152.33 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 641.98 cells per million CD4 T-cells | Standard Deviation 752.95 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 527.80 cells per million CD4 T-cells | Standard Deviation 613.23 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 1014.97 cells per million CD4 T-cells | Standard Deviation 933.09 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 434.78 cells per million CD4 T-cells | Standard Deviation 621.1 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 446.80 cells per million CD4 T-cells | Standard Deviation 736.88 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 809.46 cells per million CD4 T-cells | Standard Deviation 590.21 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 958.63 cells per million CD4 T-cells | Standard Deviation 1315.41 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 1010.24 cells per million CD4 T-cells | Standard Deviation 772.39 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 532.84 cells per million CD4 T-cells | Standard Deviation 488.63 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 332.39 cells per million CD4 T-cells | Standard Deviation 326.71 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 124.70 cells per million CD4 T-cells | Standard Deviation 306.2 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 762.07 cells per million CD4 T-cells | Standard Deviation 766.05 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 309.67 cells per million CD4 T-cells | Standard Deviation 517.11 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 118.04 cells per million CD4 T-cells | Standard Deviation 257.63 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 754.45 cells per million CD4 T-cells | Standard Deviation 694.91 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 494.63 cells per million CD4 T-cells | Standard Deviation 883.53 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 415.13 cells per million CD4 T-cells | Standard Deviation 691.39 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 606.43 cells per million CD4 T-cells | Standard Deviation 745.8 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 426.15 cells per million CD4 T-cells | Standard Deviation 660.07 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 940.53 cells per million CD4 T-cells | Standard Deviation 1065.84 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 141.26 cells per million CD4 T-cells | Standard Deviation 500.24 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 219.83 cells per million CD4 T-cells | Standard Deviation 386.13 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 817.57 cells per million CD4 T-cells | Standard Deviation 675.7 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 190.27 cells per million CD4 T-cells | Standard Deviation 322.46 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 692.82 cells per million CD4 T-cells | Standard Deviation 570.55 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 312.72 cells per million CD4 T-cells | Standard Deviation 391.89 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 1015.18 cells per million CD4 T-cells | Standard Deviation 1044.87 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 509.84 cells per million CD4 T-cells | Standard Deviation 520.06 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 250.48 cells per million CD4 T-cells | Standard Deviation 375.23 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 235.01 cells per million CD4 T-cells | Standard Deviation 355.44 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 150.59 cells per million CD4 T-cells | Standard Deviation 407.63 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 471.56 cells per million CD4 T-cells | Standard Deviation 881.73 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 279.64 cells per million CD4 T-cells | Standard Deviation 553.81 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 200.21 cells per million CD4 T-cells | Standard Deviation 480.41 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 623.21 cells per million CD4 T-cells | Standard Deviation 728.42 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 302.23 cells per million CD4 T-cells | Standard Deviation 249.59 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 251.35 cells per million CD4 T-cells | Standard Deviation 445.04 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 342.30 cells per million CD4 T-cells | Standard Deviation 455.39 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 295.56 cells per million CD4 T-cells | Standard Deviation 424.2 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 284.63 cells per million CD4 T-cells | Standard Deviation 522.58 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 409.73 cells per million CD4 T-cells | Standard Deviation 365.35 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 391.29 cells per million CD4 T-cells | Standard Deviation 474.16 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 143.44 cells per million CD4 T-cells | Standard Deviation 199.2 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 483.24 cells per million CD4 T-cells | Standard Deviation 481.37 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 379.49 cells per million CD4 T-cells | Standard Deviation 361.8 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 192.02 cells per million CD4 T-cells | Standard Deviation 314.38 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 1019.48 cells per million CD4 T-cells | Standard Deviation 698.91 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 193.35 cells per million CD4 T-cells | Standard Deviation 324.34 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 702.41 cells per million CD4 T-cells | Standard Deviation 635.67 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 511.21 cells per million CD4 T-cells | Standard Deviation 679.89 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 241.23 cells per million CD4 T-cells | Standard Deviation 332.43 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 411.11 cells per million CD4 T-cells | Standard Deviation 457.99 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 1051.06 cells per million CD4 T-cells | Standard Deviation 1024.97 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 977.44 cells per million CD4 T-cells | Standard Deviation 970.75 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 876.95 cells per million CD4 T-cells | Standard Deviation 569.97 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 651.21 cells per million CD4 T-cells | Standard Deviation 651.51 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 479.21 cells per million CD4 T-cells | Standard Deviation 550.01 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 388.89 cells per million CD4 T-cells | Standard Deviation 560.47 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 792.75 cells per million CD4 T-cells | Standard Deviation 828.41 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 975.92 cells per million CD4 T-cells | Standard Deviation 710.25 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 152.22 cells per million CD4 T-cells | Standard Deviation 284.11 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 171.07 cells per million CD4 T-cells | Standard Deviation 194.84 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 248.66 cells per million CD4 T-cells | Standard Deviation 236.24 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 518.35 cells per million CD4 T-cells | Standard Deviation 419.6 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 538.87 cells per million CD4 T-cells | Standard Deviation 691.59 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 404.64 cells per million CD4 T-cells | Standard Deviation 410.3 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 296.79 cells per million CD4 T-cells | Standard Deviation 289.33 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 611.65 cells per million CD4 T-cells | Standard Deviation 527.8 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 243.93 cells per million CD4 T-cells | Standard Deviation 321.57 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 490.56 cells per million CD4 T-cells | Standard Deviation 546.12 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 1160.31 cells per million CD4 T-cells | Standard Deviation 959.34 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 1293.10 cells per million CD4 T-cells | Standard Deviation 2390.91 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 587.17 cells per million CD4 T-cells | Standard Deviation 1872.24 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 852.80 cells per million CD4 T-cells | Standard Deviation 715.28 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 580.98 cells per million CD4 T-cells | Standard Deviation 579.68 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 167.87 cells per million CD4 T-cells | Standard Deviation 296.47 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 1038.01 cells per million CD4 T-cells | Standard Deviation 765.73 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 237.57 cells per million CD4 T-cells | Standard Deviation 200.43 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 177.44 cells per million CD4 T-cells | Standard Deviation 297.52 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 259.15 cells per million CD4 T-cells | Standard Deviation 278.35 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 137.02 cells per million CD4 T-cells | Standard Deviation 189.76 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 112.41 cells per million CD4 T-cells | Standard Deviation 169.39 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 543.09 cells per million CD4 T-cells | Standard Deviation 681.65 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 677.81 cells per million CD4 T-cells | Standard Deviation 689.59 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 600.83 cells per million CD4 T-cells | Standard Deviation 3581.08 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 157.54 cells per million CD4 T-cells | Standard Deviation 255.06 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 532.86 cells per million CD4 T-cells | Standard Deviation 708.29 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 336.45 cells per million CD4 T-cells | Standard Deviation 541.95 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 1763.75 cells per million CD4 T-cells | Standard Deviation 1858.49 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 702.79 cells per million CD4 T-cells | Standard Deviation 3741.48 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 256.73 cells per million CD4 T-cells | Standard Deviation 280.28 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 1998.33 cells per million CD4 T-cells | Standard Deviation 2730.32 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 808.90 cells per million CD4 T-cells | Standard Deviation 858.38 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 1425.03 cells per million CD4 T-cells | Standard Deviation 1236.35 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 1255.53 cells per million CD4 T-cells | Standard Deviation 941.27 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 117.51 cells per million CD4 T-cells | Standard Deviation 175 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 1293.59 cells per million CD4 T-cells | Standard Deviation 2431.45 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 495.18 cells per million CD4 T-cells | Standard Deviation 3550.69 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 269.03 cells per million CD4 T-cells | Standard Deviation 243.51 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 510.16 cells per million CD4 T-cells | Standard Deviation 871.38 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 718.87 cells per million CD4 T-cells | Standard Deviation 619.16 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 403.06 cells per million CD4 T-cells | Standard Deviation 482.16 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 303.13 cells per million CD4 T-cells | Standard Deviation 263.25 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 547.64 cells per million CD4 T-cells | Standard Deviation 464.44 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 199.80 cells per million CD4 T-cells | Standard Deviation 310.58 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 655.32 cells per million CD4 T-cells | Standard Deviation 616.75 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 457.98 cells per million CD4 T-cells | Standard Deviation 321.69 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 1234.37 cells per million CD4 T-cells | Standard Deviation 830.47 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 1153.76 cells per million CD4 T-cells | Standard Deviation 699.26 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 153.91 cells per million CD4 T-cells | Standard Deviation 311.96 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 599.32 cells per million CD4 T-cells | Standard Deviation 592.08 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 418.98 cells per million CD4 T-cells | Standard Deviation 333.83 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 1162.09 cells per million CD4 T-cells | Standard Deviation 715.63 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 383.93 cells per million CD4 T-cells | Standard Deviation 466.87 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 1039.13 cells per million CD4 T-cells | Standard Deviation 699.33 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 203.95 cells per million CD4 T-cells | Standard Deviation 254.48 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 467.66 cells per million CD4 T-cells | Standard Deviation 450.93 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 305.13 cells per million CD4 T-cells | Standard Deviation 248.4 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 277.94 cells per million CD4 T-cells | Standard Deviation 372.05 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 745.46 cells per million CD4 T-cells | Standard Deviation 575.21 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 161.81 cells per million CD4 T-cells | Standard Deviation 293.16 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 529.19 cells per million CD4 T-cells | Standard Deviation 520.65 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 393.79 cells per million CD4 T-cells | Standard Deviation 295.93 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 908.72 cells per million CD4 T-cells | Standard Deviation 680.48 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 360.78 cells per million CD4 T-cells | Standard Deviation 420.71 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 949.33 cells per million CD4 T-cells | Standard Deviation 588.11 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 100.38 cells per million CD4 T-cells | Standard Deviation 185.42 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 325.65 cells per million CD4 T-cells | Standard Deviation 410.44 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 802.15 cells per million CD4 T-cells | Standard Deviation 591.12 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 152.19 cells per million CD4 T-cells | Standard Deviation 297.33 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 1041.76 cells per million CD4 T-cells | Standard Deviation 2883.12 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 310.45 cells per million CD4 T-cells | Standard Deviation 276.1 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 170.79 cells per million CD4 T-cells | Standard Deviation 253.02 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 576.14 cells per million CD4 T-cells | Standard Deviation 4664.15 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 193.88 cells per million CD4 T-cells | Standard Deviation 141.46 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 678.22 cells per million CD4 T-cells | Standard Deviation 4760.15 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 184.52 cells per million CD4 T-cells | Standard Deviation 211.26 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 470.64 cells per million CD4 T-cells | Standard Deviation 443.13 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 957.22 cells per million CD4 T-cells | Standard Deviation 5023.06 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 431.32 cells per million CD4 T-cells | Standard Deviation 319.06 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 1156.07 cells per million CD4 T-cells | Standard Deviation 3501.25 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 568.96 cells per million CD4 T-cells | Standard Deviation 559.46 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 872.00 cells per million CD4 T-cells | Standard Deviation 4655.93 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 697.39 cells per million CD4 T-cells | Standard Deviation 5282.26 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 1057.60 cells per million CD4 T-cells | Standard Deviation 4968.52 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 165.48 cells per million CD4 T-cells | Standard Deviation 281.57 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 111.07 cells per million CD4 T-cells | Standard Deviation 179.39 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 1302.34 cells per million CD4 T-cells | Standard Deviation 3490.03 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 442.39 cells per million CD4 T-cells | Standard Deviation 315.27 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 449.86 cells per million CD4 T-cells | Standard Deviation 3979.03 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 594.26 cells per million CD4 T-cells | Standard Deviation 598.83 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 797.68 cells per million CD4 T-cells | Standard Deviation 5271.86 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 222.58 cells per million CD4 T-cells | Standard Deviation 282.91 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 540.54 cells per million CD4 T-cells | Standard Deviation 3022.19 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 420.75 cells per million CD4 T-cells | Standard Deviation 422.38 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 884.71 cells per million CD4 T-cells | Standard Deviation 2654.95 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 333.95 cells per million CD4 T-cells | Standard Deviation 309.81 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 210.23 cells per million CD4 T-cells | Standard Deviation 266.19 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 691.57 cells per million CD4 T-cells | Standard Deviation 2944.57 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 709.84 cells per million CD4 T-cells | Standard Deviation 4385.83 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 575.97 cells per million CD4 T-cells | Standard Deviation 723.76 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 122.12 cells per million CD4 T-cells | Standard Deviation 451.59 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 150.60 cells per million CD4 T-cells | Standard Deviation 512.37 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 285.50 cells per million CD4 T-cells | Standard Deviation 526.85 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 695.83 cells per million CD4 T-cells | Standard Deviation 757.57 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 406.14 cells per million CD4 T-cells | Standard Deviation 571.7 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 461.05 cells per million CD4 T-cells | Standard Deviation 498 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 781.66 cells per million CD4 T-cells | Standard Deviation 880.46 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 322.37 cells per million CD4 T-cells | Standard Deviation 713.98 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 221.19 cells per million CD4 T-cells | Standard Deviation 537.35 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 104.10 cells per million CD4 T-cells | Standard Deviation 311.25 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 301.23 cells per million CD4 T-cells | Standard Deviation 584.68 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 922.62 cells per million CD4 T-cells | Standard Deviation 1170.3 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 273.66 cells per million CD4 T-cells | Standard Deviation 355.95 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 427.71 cells per million CD4 T-cells | Standard Deviation 745.78 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 256.03 cells per million CD4 T-cells | Standard Deviation 440.55 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 536.24 cells per million CD4 T-cells | Standard Deviation 578.48 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 442.66 cells per million CD4 T-cells | Standard Deviation 449.36 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 523.15 cells per million CD4 T-cells | Standard Deviation 697.47 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 198.86 cells per million CD4 T-cells | Standard Deviation 422.78 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 327.09 cells per million CD4 T-cells | Standard Deviation 552.26 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 126.64 cells per million CD4 T-cells | Standard Deviation 402.92 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 156.21 cells per million CD4 T-cells | Standard Deviation 518.89 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 343.41 cells per million CD4 T-cells | Standard Deviation 607.93 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 707.72 cells per million CD4 T-cells | Standard Deviation 874.64 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 342.65 cells per million CD4 T-cells | Standard Deviation 589.08 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 272.34 cells per million CD4 T-cells | Standard Deviation 453.35 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 733.36 cells per million CD4 T-cells | Standard Deviation 900.95 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 548.91 cells per million CD4 T-cells | Standard Deviation 732.46 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 798.75 cells per million CD4 T-cells | Standard Deviation 1155.23 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 0 | 742.80 cells per million CD4 T-cells | Standard Deviation 659.21 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 21 | 1027.23 cells per million CD4 T-cells | Standard Deviation 838.01 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 0 | 871.60 cells per million CD4 T-cells | Standard Deviation 724.64 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 21 | 1306.18 cells per million CD4 T-cells | Standard Deviation 1346.37 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 21 | 967.83 cells per million CD4 T-cells | Standard Deviation 848.55 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 21 | 755.12 cells per million CD4 T-cells | Standard Deviation 645.89 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 21 | 805.41 cells per million CD4 T-cells | Standard Deviation 1133.76 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 0 | 589.89 cells per million CD4 T-cells | Standard Deviation 469.14 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IL2] at Day 21 | 1348.21 cells per million CD4 T-cells | Standard Deviation 1359.92 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IL2] at Day 21 | 1061.62 cells per million CD4 T-cells | Standard Deviation 635.42 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 21 | 976.96 cells per million CD4 T-cells | Standard Deviation 643.43 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-CD40L] at Day 0 | 504.55 cells per million CD4 T-cells | Standard Deviation 441.35 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 21 | 1707.62 cells per million CD4 T-cells | Standard Deviation 1591.31 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IFNγ] at Day 0 | 380.34 cells per million CD4 T-cells | Standard Deviation 384.07 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 0 | 1076.46 cells per million CD4 T-cells | Standard Deviation 903.85 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 21 | 995.86 cells per million CD4 T-cells | Standard Deviation 630.33 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-TNFα] at Day 0 | 605.04 cells per million CD4 T-cells | Standard Deviation 641.27 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-TNFα] at Day 0 | 667.60 cells per million CD4 T-cells | Standard Deviation 450.65 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 0 | 234.98 cells per million CD4 T-cells | Standard Deviation 234.23 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-All doubles] at Day 0 | 1098.75 cells per million CD4 T-cells | Standard Deviation 909.18 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-All doubles] at Day 0 | 538.72 cells per million CD4 T-cells | Standard Deviation 442.78 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 21 | 1455.68 cells per million CD4 T-cells | Standard Deviation 870.69 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-CD40L] at Day 21 | 1614.08 cells per million CD4 T-cells | Standard Deviation 1617.78 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-IFNγ] at Day 0 | 589.57 cells per million CD4 T-cells | Standard Deviation 493.89 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-All doubles] at Day 0 | 821.78 cells per million CD4 T-cells | Standard Deviation 646.48 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 21 | 813.73 cells per million CD4 T-cells | Standard Deviation 693.31 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD4-IFNγ] at Day 0 | 874.82 cells per million CD4 T-cells | Standard Deviation 729.66 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-IL2] at Day 0 | 356.84 cells per million CD4 T-cells | Standard Deviation 313.43 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD4-TNFα] at Day 21 | 490.23 cells per million CD4 T-cells | Standard Deviation 532.9 |
| Fluarix Young Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD4-CD40L] at Day 21 | 1383.25 cells per million CD4 T-cells | Standard Deviation 871.98 |
Secondary
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
The markers assessed were CD4-All doubles, CD4-CD40L, CD4-IFNγ, CD4-IL2 and CD4-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 180
Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 180.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 316.88 cells per million CD4 T-cells | Standard Deviation 297 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 522.75 cells per million CD4 T-cells | Standard Deviation 3348.47 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 621.50 cells per million CD4 T-cells | Standard Deviation 3427.5 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 679.05 cells per million CD4 T-cells | Standard Deviation 4150.67 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 549.00 cells per million CD4 T-cells | Standard Deviation 2767.21 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 722.29 cells per million CD4 T-cells | Standard Deviation 288.16 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 492.75 cells per million CD4 T-cells | Standard Deviation 320.15 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 579.40 cells per million CD4 T-cells | Standard Deviation 330.85 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 280.19 cells per million CD4 T-cells | Standard Deviation 284.35 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 348.06 cells per million CD4 T-cells | Standard Deviation 342.53 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 733.96 cells per million CD4 T-cells | Standard Deviation 397.17 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 538.21 cells per million CD4 T-cells | Standard Deviation 2445.31 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 393.50 cells per million CD4 T-cells | Standard Deviation 359.42 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 802.04 cells per million CD4 T-cells | Standard Deviation 391.96 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 244.53 cells per million CD4 T-cells | Standard Deviation 325.64 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 476.37 cells per million CD4 T-cells | Standard Deviation 416.85 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 319.80 cells per million CD4 T-cells | Standard Deviation 403.11 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 603.15 cells per million CD4 T-cells | Standard Deviation 559.07 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 314.96 cells per million CD4 T-cells | Standard Deviation 372.22 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 807.74 cells per million CD4 T-cells | Standard Deviation 629.48 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 576.09 cells per million CD4 T-cells | Standard Deviation 352.91 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 375.03 cells per million CD4 T-cells | Standard Deviation 308.38 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 764.21 cells per million CD4 T-cells | Standard Deviation 613.38 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 600.27 cells per million CD4 T-cells | Standard Deviation 472.44 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 617.40 cells per million CD4 T-cells | Standard Deviation 602.01 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 188.48 cells per million CD4 T-cells | Standard Deviation 325.58 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 510.43 cells per million CD4 T-cells | Standard Deviation 462.45 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 426.54 cells per million CD4 T-cells | Standard Deviation 422.19 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 348.12 cells per million CD4 T-cells | Standard Deviation 422.44 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 576.04 cells per million CD4 T-cells | Standard Deviation 543.29 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 698.16 cells per million CD4 T-cells | Standard Deviation 823.21 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 408.52 cells per million CD4 T-cells | Standard Deviation 712.7 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 457.89 cells per million CD4 T-cells | Standard Deviation 774.1 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 779.35 cells per million CD4 T-cells | Standard Deviation 887.41 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 626.23 cells per million CD4 T-cells | Standard Deviation 655.14 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 382.50 cells per million CD4 T-cells | Standard Deviation 490.32 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 666.01 cells per million CD4 T-cells | Standard Deviation 663.86 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 720.91 cells per million CD4 T-cells | Standard Deviation 829.77 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 807.96 cells per million CD4 T-cells | Standard Deviation 901.44 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 622.84 cells per million CD4 T-cells | Standard Deviation 626.39 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 529.59 cells per million CD4 T-cells | Standard Deviation 677.44 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 682.43 cells per million CD4 T-cells | Standard Deviation 823.68 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 392.18 cells per million CD4 T-cells | Standard Deviation 500.72 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 558.83 cells per million CD4 T-cells | Standard Deviation 549.83 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 548.14 cells per million CD4 T-cells | Standard Deviation 557.6 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 253.06 cells per million CD4 T-cells | Standard Deviation 234.64 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 372.77 cells per million CD4 T-cells | Standard Deviation 618.7 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 394.45 cells per million CD4 T-cells | Standard Deviation 508.4 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 395.86 cells per million CD4 T-cells | Standard Deviation 758.84 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 439.97 cells per million CD4 T-cells | Standard Deviation 825.94 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 416.48 cells per million CD4 T-cells | Standard Deviation 442.15 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 200.30 cells per million CD4 T-cells | Standard Deviation 422.18 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 315.90 cells per million CD4 T-cells | Standard Deviation 393.5 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 480.46 cells per million CD4 T-cells | Standard Deviation 667.59 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 280.73 cells per million CD4 T-cells | Standard Deviation 402.63 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 463.85 cells per million CD4 T-cells | Standard Deviation 832.67 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 361.05 cells per million CD4 T-cells | Standard Deviation 490.66 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 394.05 cells per million CD4 T-cells | Standard Deviation 415.93 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 304.00 cells per million CD4 T-cells | Standard Deviation 404.11 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 149.41 cells per million CD4 T-cells | Standard Deviation 359.72 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 399.91 cells per million CD4 T-cells | Standard Deviation 481 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 774.07 cells per million CD4 T-cells | Standard Deviation 452.4 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 476.90 cells per million CD4 T-cells | Standard Deviation 332.91 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 603.02 cells per million CD4 T-cells | Standard Deviation 608.61 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 411.84 cells per million CD4 T-cells | Standard Deviation 384.77 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 425.72 cells per million CD4 T-cells | Standard Deviation 346.49 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 432.70 cells per million CD4 T-cells | Standard Deviation 374.7 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 680.00 cells per million CD4 T-cells | Standard Deviation 607.45 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 743.85 cells per million CD4 T-cells | Standard Deviation 425.01 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 368.31 cells per million CD4 T-cells | Standard Deviation 348.92 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 599.10 cells per million CD4 T-cells | Standard Deviation 496.66 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 261.43 cells per million CD4 T-cells | Standard Deviation 263.15 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 263.40 cells per million CD4 T-cells | Standard Deviation 301.07 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 728.09 cells per million CD4 T-cells | Standard Deviation 640.63 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 672.69 cells per million CD4 T-cells | Standard Deviation 432.34 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 471.70 cells per million CD4 T-cells | Standard Deviation 566.4 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 160.26 cells per million CD4 T-cells | Standard Deviation 542.67 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 512.38 cells per million CD4 T-cells | Standard Deviation 740.1 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 325.70 cells per million CD4 T-cells | Standard Deviation 547.57 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 421.08 cells per million CD4 T-cells | Standard Deviation 613.81 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 350.38 cells per million CD4 T-cells | Standard Deviation 473.03 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 338.11 cells per million CD4 T-cells | Standard Deviation 488.06 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 373.28 cells per million CD4 T-cells | Standard Deviation 680.43 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 551.29 cells per million CD4 T-cells | Standard Deviation 712.29 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 240.48 cells per million CD4 T-cells | Standard Deviation 567.12 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 676.69 cells per million CD4 T-cells | Standard Deviation 785.39 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 414.76 cells per million CD4 T-cells | Standard Deviation 732.26 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 683.28 cells per million CD4 T-cells | Standard Deviation 761.14 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 400.05 cells per million CD4 T-cells | Standard Deviation 505.26 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 423.03 cells per million CD4 T-cells | Standard Deviation 839.74 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 489.69 cells per million CD4 T-cells | Standard Deviation 841.98 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 623.11 cells per million CD4 T-cells | Standard Deviation 800.89 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 357.66 cells per million CD4 T-cells | Standard Deviation 470.53 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 670.60 cells per million CD4 T-cells | Standard Deviation 881.04 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 582.68 cells per million CD4 T-cells | Standard Deviation 429.62 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 353.82 cells per million CD4 T-cells | Standard Deviation 432.84 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 592.52 cells per million CD4 T-cells | Standard Deviation 424.79 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 271.38 cells per million CD4 T-cells | Standard Deviation 373.04 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 523.69 cells per million CD4 T-cells | Standard Deviation 683.65 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 361.94 cells per million CD4 T-cells | Standard Deviation 357.95 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 304.33 cells per million CD4 T-cells | Standard Deviation 467.47 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 518.17 cells per million CD4 T-cells | Standard Deviation 374.93 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 254.19 cells per million CD4 T-cells | Standard Deviation 373.61 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 601.79 cells per million CD4 T-cells | Standard Deviation 703.08 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 360.57 cells per million CD4 T-cells | Standard Deviation 367.88 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 339.94 cells per million CD4 T-cells | Standard Deviation 440.33 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 345.05 cells per million CD4 T-cells | Standard Deviation 300.46 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 554.83 cells per million CD4 T-cells | Standard Deviation 502.42 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 228.89 cells per million CD4 T-cells | Standard Deviation 247.41 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 537.41 cells per million CD4 T-cells | Standard Deviation 351.86 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 224.47 cells per million CD4 T-cells | Standard Deviation 332.47 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 385.22 cells per million CD4 T-cells | Standard Deviation 227.19 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 234.90 cells per million CD4 T-cells | Standard Deviation 304.83 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 136.97 cells per million CD4 T-cells | Standard Deviation 262.56 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 588.22 cells per million CD4 T-cells | Standard Deviation 334.48 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 561.14 cells per million CD4 T-cells | Standard Deviation 451.82 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 360.90 cells per million CD4 T-cells | Standard Deviation 250.9 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 374.66 cells per million CD4 T-cells | Standard Deviation 407.51 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 566.79 cells per million CD4 T-cells | Standard Deviation 522.16 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 175.36 cells per million CD4 T-cells | Standard Deviation 258.68 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 691.47 cells per million CD4 T-cells | Standard Deviation 597.6 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 679.16 cells per million CD4 T-cells | Standard Deviation 486.34 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 625.97 cells per million CD4 T-cells | Standard Deviation 924.73 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 742.01 cells per million CD4 T-cells | Standard Deviation 481.8 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 638.11 cells per million CD4 T-cells | Standard Deviation 929.43 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 612.61 cells per million CD4 T-cells | Standard Deviation 455.63 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 714.85 cells per million CD4 T-cells | Standard Deviation 658.37 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 533.13 cells per million CD4 T-cells | Standard Deviation 517.19 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 700.87 cells per million CD4 T-cells | Standard Deviation 861.25 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 458.80 cells per million CD4 T-cells | Standard Deviation 456.8 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 505.39 cells per million CD4 T-cells | Standard Deviation 393.49 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 521.03 cells per million CD4 T-cells | Standard Deviation 873.58 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 467.74 cells per million CD4 T-cells | Standard Deviation 807.28 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 690.69 cells per million CD4 T-cells | Standard Deviation 642.61 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 445.44 cells per million CD4 T-cells | Standard Deviation 577.53 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-All doubles] | 1366.02 cells per million CD4 T-cells | Standard Deviation 966.33 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-All doubles] | 1304.54 cells per million CD4 T-cells | Standard Deviation 1096.3 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IL2] | 1011.95 cells per million CD4 T-cells | Standard Deviation 565.94 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IFNγ] | 1073.05 cells per million CD4 T-cells | Standard Deviation 935.35 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-TNFα] | 1187.70 cells per million CD4 T-cells | Standard Deviation 734.12 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-IFNγ] | 971.26 cells per million CD4 T-cells | Standard Deviation 783.42 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IFNγ] | 867.78 cells per million CD4 T-cells | Standard Deviation 658.04 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-IL2] | 1119.01 cells per million CD4 T-cells | Standard Deviation 801.11 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD4-CD40L] | 1268.21 cells per million CD4 T-cells | Standard Deviation 889.54 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-TNFα] | 730.49 cells per million CD4 T-cells | Standard Deviation 549.49 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-CD40L] | 999.02 cells per million CD4 T-cells | Standard Deviation 831.24 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-TNFα] | 798.97 cells per million CD4 T-cells | Standard Deviation 716.33 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD4-CD40L] | 1260.62 cells per million CD4 T-cells | Standard Deviation 1067.54 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-All doubles] | 1070.14 cells per million CD4 T-cells | Standard Deviation 874.71 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD4-IL2] | 859.06 cells per million CD4 T-cells | Standard Deviation 642.57 |
Secondary
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180
The markers assessed were CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 180
Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for cell mediated immunity (CMI) which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 21.14 cells per million CD8 T-cells | Standard Deviation 506.65 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 2.57 cells per million CD8 T-cells | Standard Deviation 89.78 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 4.15 cells per million CD8 T-cells | Standard Deviation 92.98 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 5.79 cells per million CD8 T-cells | Standard Deviation 103.71 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 1.97 cells per million CD8 T-cells | Standard Deviation 64.78 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 4.05 cells per million CD8 T-cells | Standard Deviation 74.16 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 4.21 cells per million CD8 T-cells | Standard Deviation 167.18 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 9.92 cells per million CD8 T-cells | Standard Deviation 111.75 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 10.63 cells per million CD8 T-cells | Standard Deviation 76.06 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 7.78 cells per million CD8 T-cells | Standard Deviation 244.26 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 20.60 cells per million CD8 T-cells | Standard Deviation 427.25 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 2.92 cells per million CD8 T-cells | Standard Deviation 53.08 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 2.54 cells per million CD8 T-cells | Standard Deviation 60.55 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 2.00 cells per million CD8 T-cells | Standard Deviation 54.66 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 18.75 cells per million CD8 T-cells | Standard Deviation 312.61 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 2.68 cells per million CD8 T-cells | Standard Deviation 42.6 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 3.12 cells per million CD8 T-cells | Standard Deviation 124.76 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 2.35 cells per million CD8 T-cells | Standard Deviation 31.14 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 7.10 cells per million CD8 T-cells | Standard Deviation 132.35 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 10.49 cells per million CD8 T-cells | Standard Deviation 74.37 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 4.42 cells per million CD8 T-cells | Standard Deviation 63.49 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 15.24 cells per million CD8 T-cells | Standard Deviation 108.11 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 3.72 cells per million CD8 T-cells | Standard Deviation 66.4 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 7.79 cells per million CD8 T-cells | Standard Deviation 60.25 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 12.64 cells per million CD8 T-cells | Standard Deviation 119.84 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 7.59 cells per million CD8 T-cells | Standard Deviation 100.66 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 5.64 cells per million CD8 T-cells | Standard Deviation 75.9 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 5.66 cells per million CD8 T-cells | Standard Deviation 88.74 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 14.64 cells per million CD8 T-cells | Standard Deviation 96.62 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 9.63 cells per million CD8 T-cells | Standard Deviation 110.4 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 18.10 cells per million CD8 T-cells | Standard Deviation 367.31 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 14.05 cells per million CD8 T-cells | Standard Deviation 351.12 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 2.09 cells per million CD8 T-cells | Standard Deviation 62.82 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 2.32 cells per million CD8 T-cells | Standard Deviation 92.5 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 9.25 cells per million CD8 T-cells | Standard Deviation 151.69 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 11.05 cells per million CD8 T-cells | Standard Deviation 217.46 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 3.13 cells per million CD8 T-cells | Standard Deviation 50.16 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 12.14 cells per million CD8 T-cells | Standard Deviation 319.23 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 2.95 cells per million CD8 T-cells | Standard Deviation 97.98 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 2.82 cells per million CD8 T-cells | Standard Deviation 105.05 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 10.73 cells per million CD8 T-cells | Standard Deviation 230.49 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 6.46 cells per million CD8 T-cells | Standard Deviation 183.07 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 14.08 cells per million CD8 T-cells | Standard Deviation 191.59 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 3.61 cells per million CD8 T-cells | Standard Deviation 143.1 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 10.61 cells per million CD8 T-cells | Standard Deviation 125.46 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 7.47 cells per million CD8 T-cells | Standard Deviation 77.13 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 6.19 cells per million CD8 T-cells | Standard Deviation 170.54 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 16.14 cells per million CD8 T-cells | Standard Deviation 132.83 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 6.69 cells per million CD8 T-cells | Standard Deviation 85.85 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 9.61 cells per million CD8 T-cells | Standard Deviation 157.68 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 4.75 cells per million CD8 T-cells | Standard Deviation 74.09 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 3.60 cells per million CD8 T-cells | Standard Deviation 37.07 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 3.18 cells per million CD8 T-cells | Standard Deviation 74.24 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 15.32 cells per million CD8 T-cells | Standard Deviation 145.7 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 7.48 cells per million CD8 T-cells | Standard Deviation 92.38 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 42.75 cells per million CD8 T-cells | Standard Deviation 112.35 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 3.89 cells per million CD8 T-cells | Standard Deviation 53.23 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 3.84 cells per million CD8 T-cells | Standard Deviation 93.04 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 3.36 cells per million CD8 T-cells | Standard Deviation 44.53 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 2.89 cells per million CD8 T-cells | Standard Deviation 43.98 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 11.50 cells per million CD8 T-cells | Standard Deviation 130.6 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 3.05 cells per million CD8 T-cells | Standard Deviation 107.06 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 3.97 cells per million CD8 T-cells | Standard Deviation 69.1 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 20.72 cells per million CD8 T-cells | Standard Deviation 412.35 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 1.90 cells per million CD8 T-cells | Standard Deviation 35.38 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 10.24 cells per million CD8 T-cells | Standard Deviation 49.87 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 1.62 cells per million CD8 T-cells | Standard Deviation 76.42 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 3.76 cells per million CD8 T-cells | Standard Deviation 68.56 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 2.50 cells per million CD8 T-cells | Standard Deviation 53.46 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 25.48 cells per million CD8 T-cells | Standard Deviation 138.45 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 6.11 cells per million CD8 T-cells | Standard Deviation 48.41 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 19.37 cells per million CD8 T-cells | Standard Deviation 415.28 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 6.67 cells per million CD8 T-cells | Standard Deviation 210.64 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 8.46 cells per million CD8 T-cells | Standard Deviation 105.02 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 9.60 cells per million CD8 T-cells | Standard Deviation 232.78 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 2.53 cells per million CD8 T-cells | Standard Deviation 46.46 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 1.24 cells per million CD8 T-cells | Standard Deviation 15.43 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 21.73 cells per million CD8 T-cells | Standard Deviation 368.7 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 9.18 cells per million CD8 T-cells | Standard Deviation 143.21 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 1.93 cells per million CD8 T-cells | Standard Deviation 31.31 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 8.57 cells per million CD8 T-cells | Standard Deviation 321.14 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 6.10 cells per million CD8 T-cells | Standard Deviation 113.43 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 3.12 cells per million CD8 T-cells | Standard Deviation 47.02 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 4.96 cells per million CD8 T-cells | Standard Deviation 55.7 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 1.89 cells per million CD8 T-cells | Standard Deviation 25.49 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 32.48 cells per million CD8 T-cells | Standard Deviation 357.67 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 11.62 cells per million CD8 T-cells | Standard Deviation 176.05 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 1.53 cells per million CD8 T-cells | Standard Deviation 21.24 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 3.26 cells per million CD8 T-cells | Standard Deviation 108.02 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 5.46 cells per million CD8 T-cells | Standard Deviation 88.95 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 3.86 cells per million CD8 T-cells | Standard Deviation 81.13 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 15.96 cells per million CD8 T-cells | Standard Deviation 296.44 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 2.39 cells per million CD8 T-cells | Standard Deviation 154.17 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 5.07 cells per million CD8 T-cells | Standard Deviation 415.9 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 13.90 cells per million CD8 T-cells | Standard Deviation 118.8 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 2.64 cells per million CD8 T-cells | Standard Deviation 47.18 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 4.31 cells per million CD8 T-cells | Standard Deviation 70.92 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 8.54 cells per million CD8 T-cells | Standard Deviation 430.43 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 9.09 cells per million CD8 T-cells | Standard Deviation 213.44 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 12.73 cells per million CD8 T-cells | Standard Deviation 460.97 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 3.07 cells per million CD8 T-cells | Standard Deviation 31.51 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 2.44 cells per million CD8 T-cells | Standard Deviation 28.8 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 2.70 cells per million CD8 T-cells | Standard Deviation 59.56 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 21.00 cells per million CD8 T-cells | Standard Deviation 327.24 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 3.77 cells per million CD8 T-cells | Standard Deviation 59.02 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 4.89 cells per million CD8 T-cells | Standard Deviation 86.67 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 3.11 cells per million CD8 T-cells | Standard Deviation 45.39 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 3.67 cells per million CD8 T-cells | Standard Deviation 78.9 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 2.75 cells per million CD8 T-cells | Standard Deviation 73.05 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 11.89 cells per million CD8 T-cells | Standard Deviation 385.26 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 6.00 cells per million CD8 T-cells | Standard Deviation 315.87 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 5.99 cells per million CD8 T-cells | Standard Deviation 110.92 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 4.89 cells per million CD8 T-cells | Standard Deviation 86.67 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 3.63 cells per million CD8 T-cells | Standard Deviation 81.27 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 2.73 cells per million CD8 T-cells | Standard Deviation 44.5 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 4.71 cells per million CD8 T-cells | Standard Deviation 115.31 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 11.95 cells per million CD8 T-cells | Standard Deviation 384.28 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 4.86 cells per million CD8 T-cells | Standard Deviation 78.63 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 4.81 cells per million CD8 T-cells | Standard Deviation 90.76 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 2.56 cells per million CD8 T-cells | Standard Deviation 40.61 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 8.74 cells per million CD8 T-cells | Standard Deviation 100.11 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 7.32 cells per million CD8 T-cells | Standard Deviation 115.74 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 3.63 cells per million CD8 T-cells | Standard Deviation 81.37 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 6.47 cells per million CD8 T-cells | Standard Deviation 83.62 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 1.97 cells per million CD8 T-cells | Standard Deviation 157.41 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 2.54 cells per million CD8 T-cells | Standard Deviation 79.84 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 4.12 cells per million CD8 T-cells | Standard Deviation 49.87 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 10.44 cells per million CD8 T-cells | Standard Deviation 226.57 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 4.69 cells per million CD8 T-cells | Standard Deviation 42.36 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 4.93 cells per million CD8 T-cells | Standard Deviation 111.36 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 6.81 cells per million CD8 T-cells | Standard Deviation 139.38 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 6.46 cells per million CD8 T-cells | Standard Deviation 135.88 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 2.36 cells per million CD8 T-cells | Standard Deviation 55.08 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 10.37 cells per million CD8 T-cells | Standard Deviation 212.91 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 4.38 cells per million CD8 T-cells | Standard Deviation 95.85 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IL2] | 4.04 cells per million CD8 T-cells | Standard Deviation 153.21 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-CD40L] | 3.94 cells per million CD8 T-cells | Standard Deviation 40.79 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IFNγ] | 5.33 cells per million CD8 T-cells | Standard Deviation 182.33 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-All doubles] | 7.96 cells per million CD8 T-cells | Standard Deviation 132.07 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-IL2] | 6.11 cells per million CD8 T-cells | Standard Deviation 91.97 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-IFNγ] | 2.72 cells per million CD8 T-cells | Standard Deviation 125.7 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-CD40L] | 3.78 cells per million CD8 T-cells | Standard Deviation 95.38 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-TNFα] | 3.52 cells per million CD8 T-cells | Standard Deviation 125.46 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-CD40L] | 3.43 cells per million CD8 T-cells | Standard Deviation 66.51 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-TNFα] | 3.39 cells per million CD8 T-cells | Standard Deviation 69.3 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | B/Malaysia [CD8-TNFα] | 4.58 cells per million CD8 T-cells | Standard Deviation 132.21 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IL2] | 7.15 cells per million CD8 T-cells | Standard Deviation 75.19 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Wisconsin [CD8-All doubles] | 3.13 cells per million CD8 T-cells | Standard Deviation 186.12 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-All doubles] | 5.64 cells per million CD8 T-cells | Standard Deviation 98.76 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Day 180 | A/Solomon Islands [CD8-IFNγ] | 2.65 cells per million CD8 T-cells | Standard Deviation 79.58 |
Secondary
The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21
The markers assessed were Cluster of Differentiation 8-All doubles i.e. CD8-All doubles, CD8-CD40L, CD8-IFNγ, CD8-IL2 and CD8-TNFα. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Days 0 and 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 42.50 cells per million CD8 T-cells | Standard Deviation 296.07 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 7.45 cells per million CD8 T-cells | Standard Deviation 97.1 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 5.04 cells per million CD8 T-cells | Standard Deviation 145.4 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 11.62 cells per million CD8 T-cells | Standard Deviation 200.31 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 3.70 cells per million CD8 T-cells | Standard Deviation 113.92 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 14.64 cells per million CD8 T-cells | Standard Deviation 98.8 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 31.08 cells per million CD8 T-cells | Standard Deviation 84.59 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 12.45 cells per million CD8 T-cells | Standard Deviation 89.54 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 2.68 cells per million CD8 T-cells | Standard Deviation 127.6 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 8.27 cells per million CD8 T-cells | Standard Deviation 78.96 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 5.56 cells per million CD8 T-cells | Standard Deviation 99.28 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 7.85 cells per million CD8 T-cells | Standard Deviation 103.62 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 3.24 cells per million CD8 T-cells | Standard Deviation 54.73 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 8.66 cells per million CD8 T-cells | Standard Deviation 147.36 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 3.09 cells per million CD8 T-cells | Standard Deviation 45.67 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 4.80 cells per million CD8 T-cells | Standard Deviation 63.95 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 28.50 cells per million CD8 T-cells | Standard Deviation 261.61 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 11.69 cells per million CD8 T-cells | Standard Deviation 129.41 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 8.10 cells per million CD8 T-cells | Standard Deviation 135.4 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 4.63 cells per million CD8 T-cells | Standard Deviation 51.86 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 17.85 cells per million CD8 T-cells | Standard Deviation 257.14 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 3.76 cells per million CD8 T-cells | Standard Deviation 69.81 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 5.41 cells per million CD8 T-cells | Standard Deviation 91.54 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 7.38 cells per million CD8 T-cells | Standard Deviation 115.6 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 11.49 cells per million CD8 T-cells | Standard Deviation 167.4 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 7.37 cells per million CD8 T-cells | Standard Deviation 84.04 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 9.69 cells per million CD8 T-cells | Standard Deviation 178.06 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 3.52 cells per million CD8 T-cells | Standard Deviation 80.5 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 7.68 cells per million CD8 T-cells | Standard Deviation 76.49 |
| Influenza Vaccine GSK576389A Formulation 1 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 3.79 cells per million CD8 T-cells | Standard Deviation 79.93 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 5.93 cells per million CD8 T-cells | Standard Deviation 78.91 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 8.63 cells per million CD8 T-cells | Standard Deviation 176.22 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 10.71 cells per million CD8 T-cells | Standard Deviation 390.44 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 12.20 cells per million CD8 T-cells | Standard Deviation 127.89 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 17.80 cells per million CD8 T-cells | Standard Deviation 305.22 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 11.28 cells per million CD8 T-cells | Standard Deviation 215.17 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 6.81 cells per million CD8 T-cells | Standard Deviation 126.03 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 5.75 cells per million CD8 T-cells | Standard Deviation 118.21 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 7.54 cells per million CD8 T-cells | Standard Deviation 234.23 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 3.70 cells per million CD8 T-cells | Standard Deviation 138.04 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 15.68 cells per million CD8 T-cells | Standard Deviation 423.52 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 12.06 cells per million CD8 T-cells | Standard Deviation 265.01 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 44.96 cells per million CD8 T-cells | Standard Deviation 351.05 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 12.15 cells per million CD8 T-cells | Standard Deviation 70.97 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 9.18 cells per million CD8 T-cells | Standard Deviation 141.09 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 3.26 cells per million CD8 T-cells | Standard Deviation 34.12 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 3.41 cells per million CD8 T-cells | Standard Deviation 98.02 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 32.92 cells per million CD8 T-cells | Standard Deviation 72.84 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 2.17 cells per million CD8 T-cells | Standard Deviation 41.97 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 13.76 cells per million CD8 T-cells | Standard Deviation 122.97 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 5.72 cells per million CD8 T-cells | Standard Deviation 165.77 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 4.40 cells per million CD8 T-cells | Standard Deviation 161.85 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 7.16 cells per million CD8 T-cells | Standard Deviation 290.97 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 3.21 cells per million CD8 T-cells | Standard Deviation 91.01 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 8.63 cells per million CD8 T-cells | Standard Deviation 157.7 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 12.90 cells per million CD8 T-cells | Standard Deviation 151.71 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 9.19 cells per million CD8 T-cells | Standard Deviation 85.93 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 4.30 cells per million CD8 T-cells | Standard Deviation 73.39 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 3.95 cells per million CD8 T-cells | Standard Deviation 78.12 |
| Influenza Vaccine GSK576389A Formulation 2 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 3.10 cells per million CD8 T-cells | Standard Deviation 27.39 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 14.44 cells per million CD8 T-cells | Standard Deviation 160.52 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 30.58 cells per million CD8 T-cells | Standard Deviation 282.37 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 9.54 cells per million CD8 T-cells | Standard Deviation 116.11 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 7.70 cells per million CD8 T-cells | Standard Deviation 64.46 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 8.71 cells per million CD8 T-cells | Standard Deviation 71.14 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 10.05 cells per million CD8 T-cells | Standard Deviation 141.49 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 6.53 cells per million CD8 T-cells | Standard Deviation 132.89 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 9.89 cells per million CD8 T-cells | Standard Deviation 295.99 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 4.19 cells per million CD8 T-cells | Standard Deviation 52.99 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 20.54 cells per million CD8 T-cells | Standard Deviation 188.5 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 7.61 cells per million CD8 T-cells | Standard Deviation 309.89 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 14.46 cells per million CD8 T-cells | Standard Deviation 122.65 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 5.50 cells per million CD8 T-cells | Standard Deviation 55.47 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 18.47 cells per million CD8 T-cells | Standard Deviation 194.16 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 15.15 cells per million CD8 T-cells | Standard Deviation 261.46 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 5.74 cells per million CD8 T-cells | Standard Deviation 278.42 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 5.31 cells per million CD8 T-cells | Standard Deviation 338.73 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 9.77 cells per million CD8 T-cells | Standard Deviation 292.05 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 8.71 cells per million CD8 T-cells | Standard Deviation 75.81 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 9.85 cells per million CD8 T-cells | Standard Deviation 344.91 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 10.16 cells per million CD8 T-cells | Standard Deviation 107.21 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 9.28 cells per million CD8 T-cells | Standard Deviation 142.76 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 11.15 cells per million CD8 T-cells | Standard Deviation 94.57 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 9.72 cells per million CD8 T-cells | Standard Deviation 118.83 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 6.13 cells per million CD8 T-cells | Standard Deviation 99.85 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 3.74 cells per million CD8 T-cells | Standard Deviation 115.89 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 7.64 cells per million CD8 T-cells | Standard Deviation 81.73 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 7.50 cells per million CD8 T-cells | Standard Deviation 51.96 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 5.20 cells per million CD8 T-cells | Standard Deviation 70.37 |
| Influenza Vaccine GSK576389A Formulation 3 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 2.76 cells per million CD8 T-cells | Standard Deviation 117.87 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 8.09 cells per million CD8 T-cells | Standard Deviation 302.34 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 9.21 cells per million CD8 T-cells | Standard Deviation 224.57 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 3.93 cells per million CD8 T-cells | Standard Deviation 124.78 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 2.59 cells per million CD8 T-cells | Standard Deviation 42.2 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 2.31 cells per million CD8 T-cells | Standard Deviation 25.28 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 2.18 cells per million CD8 T-cells | Standard Deviation 51.19 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 2.20 cells per million CD8 T-cells | Standard Deviation 47.58 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 4.83 cells per million CD8 T-cells | Standard Deviation 129.69 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 5.14 cells per million CD8 T-cells | Standard Deviation 87.63 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 3.03 cells per million CD8 T-cells | Standard Deviation 42.1 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 1.82 cells per million CD8 T-cells | Standard Deviation 70.4 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 3.52 cells per million CD8 T-cells | Standard Deviation 66.86 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 9.50 cells per million CD8 T-cells | Standard Deviation 106.18 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 3.00 cells per million CD8 T-cells | Standard Deviation 45.24 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 6.09 cells per million CD8 T-cells | Standard Deviation 157.93 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 3.05 cells per million CD8 T-cells | Standard Deviation 40.35 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 2.82 cells per million CD8 T-cells | Standard Deviation 87.95 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 3.25 cells per million CD8 T-cells | Standard Deviation 53.78 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 5.42 cells per million CD8 T-cells | Standard Deviation 269.73 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 4.45 cells per million CD8 T-cells | Standard Deviation 142.55 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 3.13 cells per million CD8 T-cells | Standard Deviation 61.75 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 2.46 cells per million CD8 T-cells | Standard Deviation 120.14 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 8.77 cells per million CD8 T-cells | Standard Deviation 177.85 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 3.99 cells per million CD8 T-cells | Standard Deviation 62.89 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 4.15 cells per million CD8 T-cells | Standard Deviation 66.82 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 3.70 cells per million CD8 T-cells | Standard Deviation 67.7 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 10.85 cells per million CD8 T-cells | Standard Deviation 215.2 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 3.97 cells per million CD8 T-cells | Standard Deviation 61.17 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 3.47 cells per million CD8 T-cells | Standard Deviation 65.17 |
| Influenza Vaccine GSK576389A Formulation 4 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 5.85 cells per million CD8 T-cells | Standard Deviation 65.6 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 6.74 cells per million CD8 T-cells | Standard Deviation 63.87 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 6.18 cells per million CD8 T-cells | Standard Deviation 125.9 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 2.58 cells per million CD8 T-cells | Standard Deviation 39.14 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 14.05 cells per million CD8 T-cells | Standard Deviation 224.41 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 1.20 cells per million CD8 T-cells | Standard Deviation 13.14 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 5.23 cells per million CD8 T-cells | Standard Deviation 75.71 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 3.22 cells per million CD8 T-cells | Standard Deviation 72.42 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 2.68 cells per million CD8 T-cells | Standard Deviation 61.45 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 4.69 cells per million CD8 T-cells | Standard Deviation 90.75 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 31.02 cells per million CD8 T-cells | Standard Deviation 243.07 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 7.73 cells per million CD8 T-cells | Standard Deviation 139.86 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 3.96 cells per million CD8 T-cells | Standard Deviation 75.52 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 8.64 cells per million CD8 T-cells | Standard Deviation 86.13 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 2.75 cells per million CD8 T-cells | Standard Deviation 106.31 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 15.20 cells per million CD8 T-cells | Standard Deviation 160.37 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 6.77 cells per million CD8 T-cells | Standard Deviation 50.82 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 2.97 cells per million CD8 T-cells | Standard Deviation 61.7 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 5.72 cells per million CD8 T-cells | Standard Deviation 90.85 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 10.28 cells per million CD8 T-cells | Standard Deviation 61.17 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 7.60 cells per million CD8 T-cells | Standard Deviation 27.9 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 2.84 cells per million CD8 T-cells | Standard Deviation 47.37 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 1.98 cells per million CD8 T-cells | Standard Deviation 40.41 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 2.13 cells per million CD8 T-cells | Standard Deviation 22.15 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 2.78 cells per million CD8 T-cells | Standard Deviation 66.95 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 5.60 cells per million CD8 T-cells | Standard Deviation 66.01 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 2.11 cells per million CD8 T-cells | Standard Deviation 71.74 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 4.87 cells per million CD8 T-cells | Standard Deviation 92.78 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 6.67 cells per million CD8 T-cells | Standard Deviation 112.61 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 9.13 cells per million CD8 T-cells | Standard Deviation 183.09 |
| Influenza Vaccine GSK576389A Formulation 5 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 3.31 cells per million CD8 T-cells | Standard Deviation 91.6 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 2.66 cells per million CD8 T-cells | Standard Deviation 49.28 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 2.31 cells per million CD8 T-cells | Standard Deviation 47.88 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 4.71 cells per million CD8 T-cells | Standard Deviation 49.37 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 5.53 cells per million CD8 T-cells | Standard Deviation 169.17 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 12.49 cells per million CD8 T-cells | Standard Deviation 189.06 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 2.48 cells per million CD8 T-cells | Standard Deviation 44.95 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 22.20 cells per million CD8 T-cells | Standard Deviation 183.56 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 1.47 cells per million CD8 T-cells | Standard Deviation 26.08 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 2.21 cells per million CD8 T-cells | Standard Deviation 42.86 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 1.47 cells per million CD8 T-cells | Standard Deviation 26.82 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 5.01 cells per million CD8 T-cells | Standard Deviation 88.79 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 1.66 cells per million CD8 T-cells | Standard Deviation 34.2 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 5.64 cells per million CD8 T-cells | Standard Deviation 138.31 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 1.89 cells per million CD8 T-cells | Standard Deviation 57.5 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 2.03 cells per million CD8 T-cells | Standard Deviation 23 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 2.51 cells per million CD8 T-cells | Standard Deviation 168.1 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 10.28 cells per million CD8 T-cells | Standard Deviation 119.1 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 1.69 cells per million CD8 T-cells | Standard Deviation 19.96 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 9.75 cells per million CD8 T-cells | Standard Deviation 159.06 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 2.12 cells per million CD8 T-cells | Standard Deviation 30.13 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 4.86 cells per million CD8 T-cells | Standard Deviation 57.41 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 4.05 cells per million CD8 T-cells | Standard Deviation 62.37 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 4.41 cells per million CD8 T-cells | Standard Deviation 109.49 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 8.49 cells per million CD8 T-cells | Standard Deviation 137.21 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 2.28 cells per million CD8 T-cells | Standard Deviation 45.26 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 3.78 cells per million CD8 T-cells | Standard Deviation 51.36 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 9.54 cells per million CD8 T-cells | Standard Deviation 187.33 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 12.32 cells per million CD8 T-cells | Standard Deviation 188.66 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 2.67 cells per million CD8 T-cells | Standard Deviation 37.22 |
| Influenza Vaccine GSK576389A Formulation 6 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 9.02 cells per million CD8 T-cells | Standard Deviation 96.93 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 26.27 cells per million CD8 T-cells | Standard Deviation 218.28 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 5.33 cells per million CD8 T-cells | Standard Deviation 36.95 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 3.29 cells per million CD8 T-cells | Standard Deviation 76.69 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 9.62 cells per million CD8 T-cells | Standard Deviation 50.39 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 2.39 cells per million CD8 T-cells | Standard Deviation 55.56 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 5.60 cells per million CD8 T-cells | Standard Deviation 50.57 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 10.92 cells per million CD8 T-cells | Standard Deviation 109.83 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 23.95 cells per million CD8 T-cells | Standard Deviation 323.71 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 17.27 cells per million CD8 T-cells | Standard Deviation 129.27 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 4.36 cells per million CD8 T-cells | Standard Deviation 36.32 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 16.86 cells per million CD8 T-cells | Standard Deviation 219.38 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 5.58 cells per million CD8 T-cells | Standard Deviation 98.17 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 3.28 cells per million CD8 T-cells | Standard Deviation 81.61 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 5.96 cells per million CD8 T-cells | Standard Deviation 128.54 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 8.97 cells per million CD8 T-cells | Standard Deviation 271.08 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 3.10 cells per million CD8 T-cells | Standard Deviation 43.93 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 12.10 cells per million CD8 T-cells | Standard Deviation 182.42 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 26.25 cells per million CD8 T-cells | Standard Deviation 172.19 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 4.70 cells per million CD8 T-cells | Standard Deviation 53.61 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 11.29 cells per million CD8 T-cells | Standard Deviation 211.8 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 60.96 cells per million CD8 T-cells | Standard Deviation 415.86 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 5.41 cells per million CD8 T-cells | Standard Deviation 65.29 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 2.63 cells per million CD8 T-cells | Standard Deviation 98.13 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 3.36 cells per million CD8 T-cells | Standard Deviation 55.81 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 8.19 cells per million CD8 T-cells | Standard Deviation 95.91 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 27.84 cells per million CD8 T-cells | Standard Deviation 355.89 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 17.98 cells per million CD8 T-cells | Standard Deviation 127.27 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 2.18 cells per million CD8 T-cells | Standard Deviation 33.72 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 3.04 cells per million CD8 T-cells | Standard Deviation 89.37 |
| Influenza Vaccine GSK576389A Formulation 7 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 12.07 cells per million CD8 T-cells | Standard Deviation 140.1 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 10.06 cells per million CD8 T-cells | Standard Deviation 78.63 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 2.94 cells per million CD8 T-cells | Standard Deviation 67.71 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 5.63 cells per million CD8 T-cells | Standard Deviation 58.18 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 13.39 cells per million CD8 T-cells | Standard Deviation 193.75 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 4.99 cells per million CD8 T-cells | Standard Deviation 168.28 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 5.57 cells per million CD8 T-cells | Standard Deviation 83.12 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 23.57 cells per million CD8 T-cells | Standard Deviation 184.06 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 6.03 cells per million CD8 T-cells | Standard Deviation 110.26 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 17.76 cells per million CD8 T-cells | Standard Deviation 137.26 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 23.27 cells per million CD8 T-cells | Standard Deviation 109.52 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 4.47 cells per million CD8 T-cells | Standard Deviation 183.7 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 3.18 cells per million CD8 T-cells | Standard Deviation 106.55 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 6.43 cells per million CD8 T-cells | Standard Deviation 82.32 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 2.96 cells per million CD8 T-cells | Standard Deviation 40.4 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 6.83 cells per million CD8 T-cells | Standard Deviation 67.42 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 18.53 cells per million CD8 T-cells | Standard Deviation 162.45 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 5.21 cells per million CD8 T-cells | Standard Deviation 59 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 4.02 cells per million CD8 T-cells | Standard Deviation 92.71 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 6.18 cells per million CD8 T-cells | Standard Deviation 125.87 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 4.76 cells per million CD8 T-cells | Standard Deviation 132.76 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 5.17 cells per million CD8 T-cells | Standard Deviation 34.65 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 8.52 cells per million CD8 T-cells | Standard Deviation 135.47 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 4.05 cells per million CD8 T-cells | Standard Deviation 52.57 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 2.08 cells per million CD8 T-cells | Standard Deviation 53.94 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 17.14 cells per million CD8 T-cells | Standard Deviation 88.2 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 15.64 cells per million CD8 T-cells | Standard Deviation 126.07 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 6.83 cells per million CD8 T-cells | Standard Deviation 63.62 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 3.45 cells per million CD8 T-cells | Standard Deviation 82.08 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 6.73 cells per million CD8 T-cells | Standard Deviation 108.1 |
| Influenza Vaccine GSK576389A Formulation 8 Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 5.19 cells per million CD8 T-cells | Standard Deviation 81.07 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 10.48 cells per million CD8 T-cells | Standard Deviation 95.48 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 7.23 cells per million CD8 T-cells | Standard Deviation 129.33 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 4.00 cells per million CD8 T-cells | Standard Deviation 42.26 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 3.25 cells per million CD8 T-cells | Standard Deviation 64.56 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 8.68 cells per million CD8 T-cells | Standard Deviation 98.54 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 7.30 cells per million CD8 T-cells | Standard Deviation 69.21 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 3.43 cells per million CD8 T-cells | Standard Deviation 72.64 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 3.75 cells per million CD8 T-cells | Standard Deviation 71.92 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 5.52 cells per million CD8 T-cells | Standard Deviation 168.72 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 7.27 cells per million CD8 T-cells | Standard Deviation 43.58 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 14.11 cells per million CD8 T-cells | Standard Deviation 81.52 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 4.55 cells per million CD8 T-cells | Standard Deviation 93.16 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 6.41 cells per million CD8 T-cells | Standard Deviation 108.44 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 2.30 cells per million CD8 T-cells | Standard Deviation 53.4 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 7.95 cells per million CD8 T-cells | Standard Deviation 75.16 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 24.91 cells per million CD8 T-cells | Standard Deviation 153.61 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 3.94 cells per million CD8 T-cells | Standard Deviation 52.44 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 16.83 cells per million CD8 T-cells | Standard Deviation 232.88 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 4.35 cells per million CD8 T-cells | Standard Deviation 64.5 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 39.03 cells per million CD8 T-cells | Standard Deviation 123 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 3.93 cells per million CD8 T-cells | Standard Deviation 93.43 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 8.22 cells per million CD8 T-cells | Standard Deviation 153.57 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 16.28 cells per million CD8 T-cells | Standard Deviation 142.2 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 6.33 cells per million CD8 T-cells | Standard Deviation 91.54 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 13.81 cells per million CD8 T-cells | Standard Deviation 116.94 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 19.42 cells per million CD8 T-cells | Standard Deviation 124.13 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 9.94 cells per million CD8 T-cells | Standard Deviation 190.65 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 6.94 cells per million CD8 T-cells | Standard Deviation 109.72 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 14.97 cells per million CD8 T-cells | Standard Deviation 169.37 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 21.99 cells per million CD8 T-cells | Standard Deviation 122.96 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 0 | 9.16 cells per million CD8 T-cells | Standard Deviation 63.84 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 21 | 1.59 cells per million CD8 T-cells | Standard Deviation 141.41 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IFNγ] at Day 0 | 4.59 cells per million CD8 T-cells | Standard Deviation 65.86 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 0 | 2.70 cells per million CD8 T-cells | Standard Deviation 77.94 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 21 | 2.34 cells per million CD8 T-cells | Standard Deviation 132.36 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-CD40L] at Day 21 | 2.97 cells per million CD8 T-cells | Standard Deviation 43.37 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 0 | 2.17 cells per million CD8 T-cells | Standard Deviation 64.13 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 0 | 2.96 cells per million CD8 T-cells | Standard Deviation 99.03 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 21 | 2.21 cells per million CD8 T-cells | Standard Deviation 47.9 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 21 | 2.52 cells per million CD8 T-cells | Standard Deviation 46.95 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IFNγ] at Day 0 | 7.26 cells per million CD8 T-cells | Standard Deviation 64.6 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 21 | 2.69 cells per million CD8 T-cells | Standard Deviation 51.22 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-CD40L] at Day 21 | 2.04 cells per million CD8 T-cells | Standard Deviation 35.04 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 0 | 2.67 cells per million CD8 T-cells | Standard Deviation 38.98 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-IL2] at Day 0 | 2.00 cells per million CD8 T-cells | Standard Deviation 23.96 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 21 | 12.44 cells per million CD8 T-cells | Standard Deviation 163.33 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 0 | 3.98 cells per million CD8 T-cells | Standard Deviation 95.04 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-CD40L] at Day 21 | 9.50 cells per million CD8 T-cells | Standard Deviation 127.97 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 0 | 9.07 cells per million CD8 T-cells | Standard Deviation 123.64 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 21 | 1.91 cells per million CD8 T-cells | Standard Deviation 131.67 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-TNFα] at Day 21 | 8.57 cells per million CD8 T-cells | Standard Deviation 151.66 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-All doubles] at Day 21 | 2.00 cells per million CD8 T-cells | Standard Deviation 57.24 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IFNγ] at Day 0 | 9.07 cells per million CD8 T-cells | Standard Deviation 168.5 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 0 | 11.02 cells per million CD8 T-cells | Standard Deviation 175.35 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-TNFα] at Day 0 | 4.33 cells per million CD8 T-cells | Standard Deviation 81.83 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-All doubles] at Day 0 | 7.69 cells per million CD8 T-cells | Standard Deviation 91.4 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-All doubles] at Day 21 | 16.20 cells per million CD8 T-cells | Standard Deviation 225.18 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | B/Malaysia [CD8-IL2] at Day 21 | 12.46 cells per million CD8 T-cells | Standard Deviation 96.16 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Solomon Islands [CD8-IL2] at Day 21 | 2.17 cells per million CD8 T-cells | Standard Deviation 44.9 |
| Fluarix Young Group | The GM Number of Influenza-specific CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker at Days 0 and 21 | A/Wisconsin [CD8-TNFα] at Day 0 | 3.41 cells per million CD8 T-cells | Standard Deviation 64.37 |
Secondary
The Number of Subjects Seroconverted to HI Antibodies at Day 180
A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 180
Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 47 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 64 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 23 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 23 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 73 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 59 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 25 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 74 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 61 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 68 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 19 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 46 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 16 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 60 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 50 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 32 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 74 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 77 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 60 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 37 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 19 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 49 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 20 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 67 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 17 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 42 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 23 Subjects |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Wisconsin strain | 74 Subjects |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | A/Solomon Islands strain | 90 Subjects |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies at Day 180 | B/Malaysia strain | 90 Subjects |
Secondary
The Number of Subjects Seroconverted to HI Antibodies at Day 21
A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 108 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 133 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 47 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 124 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 73 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 138 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 141 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 154 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 65 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 130 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 104 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 44 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 142 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 45 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 124 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 79 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 142 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 151 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 129 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 110 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 50 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 131 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 146 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 55 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 47 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 99 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 69 Subjects |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | B/Malaysia strain | 147 Subjects |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Solomon Islands strain | 135 Subjects |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies at Day 21 | A/Wisconsin strain | 130 Subjects |
Secondary
The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21
A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 0 and 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 133 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 27 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 188 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 183 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 160 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 138 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 168 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 31 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 189 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 124 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 140 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 183 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 113 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 188 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 138 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 25 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 171 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 184 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 190 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 33 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 187 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 158 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 139 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 148 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 156 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 192 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 131 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 186 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 169 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 44 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 192 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 172 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 149 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 139 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 191 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 23 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 130 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 182 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 22 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 153 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 187 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 139 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 184 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 163 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 145 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 134 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 185 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 26 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 132 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 31 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 183 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 144 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 179 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 132 Subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 21 | 197 Subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 21 | 182 Subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Solomon Islands strain at Day 0 | 69 Subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 0 | 77 Subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | B/Malaysia strain at Day 21 | 195 Subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies at Day 0 and 21 | A/Wisconsin strain at Day 0 | 122 Subjects |
Secondary
The Number of Subjects Seroprotected to HI Antibodies at Day 180
A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 180
Population: Analysis was performed on According-to-Protocol (ATP) cohort for persistence for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 180.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 94 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 167 Subjects |
| Influenza Vaccine GSK576389A Formulation 1 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 172 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 170 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 166 Subjects |
| Influenza Vaccine GSK576389A Formulation 2 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 111 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 168 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 105 Subjects |
| Influenza Vaccine GSK576389A Formulation 3 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 162 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 168 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 105 Subjects |
| Influenza Vaccine GSK576389A Formulation 4 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 164 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 103 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 170 Subjects |
| Influenza Vaccine GSK576389A Formulation 5 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 166 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 179 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 104 Subjects |
| Influenza Vaccine GSK576389A Formulation 6 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 176 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 100 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 158 Subjects |
| Influenza Vaccine GSK576389A Formulation 7 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 166 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 160 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 100 Subjects |
| Influenza Vaccine GSK576389A Formulation 8 Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 162 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 156 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 77 Subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 162 Subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Solomon Islands strain | 135 Subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | B/Malaysia strain | 144 Subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies at Day 180 | A/Wisconsin strain | 158 Subjects |